Optimization, Validation and Implementation of Retroviral Retentive Filters for Production of Adeno-Associated Virus (AAV)

Viral contamination is a risk for all biotechnology products. Establishing robust viral removal/inactivation steps mitigates the risk of adventitious and endogenous viral contamination and is essential for ensuring the safety of gene therapy products. AGTC employs helper virus, a recombinant herpes simplex virus type 1 (HSV), to manufacture therapeutic AAV vectors.

Recent studies have shown that viral retentive filtration is one of the most robust steps in removing all types of viruses. In order to ensure the removal of endogenous and adventitious viral contaminants, AGTC is developing a viral filtration step after the downstream column purification.

First Name *

Last Name *

Email *

Company Name *

Company Type *

Job Function *

Job Level *

Dive Publication

Field will not be visible to web visitor

By completing this form, you agree to our Terms of Use, Privacy Policy, and your information being shared with our sponsor, Millipore.*

Optimization, Validation and Implementation of Retroviral Retentive Filters for Production of Adeno-Associated Virus (AAV)

GET THE APPLICATION NOTE

Form submitted successfully.

Please verify your mobile number